Evidence Limits in BPC-157, TB-500, and Soft Tissue Research Evidence in this area can include cell studies, animal studies, pathway research, formulation testing, stability studies, pharmacokinetic research, sports medicine studies, clinical trials, rehabilitation studies, safety reviews, and patient-reported outcomes
The BPC-157 (10mg) and TB-500 (20mg) blend is a widely studied combination in research environments
Here's the deal
Similarly, after ruling out IC and other causes, BPS can be treated symptomatically
In certain embodiments, the preservative employed in any auris-compatible formulation described herein is an antioxidant (e.g., butyl hydroxytoluene (BHT) or the like, as described herein)